XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization $ 543 $ 699  
Sales 14,487 15,901  
Operating Segments      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 14,212 15,589  
Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 12,721 14,107  
Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization   250  
Lynparza | Other Noncurrent Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 1,500    
Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization 72    
Lenvima | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 232 227  
Lenvima | Other Noncurrent Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 812    
Verquvo | Other Intangible Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 56    
Adempas | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 59 61  
Adempas | Other Intangible Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 613    
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 43 52  
AstraZeneca | Sales-Based Milestones | Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments   600  
Liabilities   600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   400  
Potential future sales-based milestone payments 2,100    
Regulatory milestone payments accrued     $ 105
Capitalized milestone payment     250
Potential future regulatory milestone payments 1,100    
Eisai | Sales-Based Milestones | Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments 125    
Liabilities 125    
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   300 600
Potential future sales-based milestone payments $ 2,400    
Capitalized milestone payment   25 $ 50
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   400  
Bristol Myers Squibb | Licensing Agreements      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate, deduction 0.50    
Royalties   32  
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contingent proceeds collaborative arrangement $ 80    
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Proceeds from Collaborators   $ 20  
Bristol Myers Squibb | Licensing Agreements | Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate 20.00%    
Bristol Myers Squibb | Licensing Agreements | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate 24.00%